No connection between ARBs and cancer
In 2010, a controversial analysis suggested that angiotensin-receptor blockers (ARBs) increased the risk of developing cancer, especially lung cancer. Not so, says an FDA safety alert issued in June 2011.
ARBs are widely used to treat high blood pressure. They include azilsartan medoxomil (Edarbi), candesartan (Atacand), eprosartan (Teveten), irbesartan (Avapro), losartan (Cozaar, generic), olmesartan (Benicar), telmisartan (Micardis), and valsartan (Diovan). Several combination drugs include an ARB plus a diuretic or a calcium-channel blocker.